NCT03474042 - GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

April 10, 2018

Study Completion Date

April 10, 2018

Conditions

Cystic Fibrosis

Interventions

DRUG

GLPG2737

GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.

DRUG

Placebo

Placebo oral capsules administered twice daily for 28 days on top of Orkambi.

Trial Locations (9)

Study Site II, Berlin

Study Site V, Cologne

Study Site X, Dresden

Study Site III, Essen

Study Site IV, Frankfurt

Study Site I, Heidelberg

Study Site VI, München

Study Site IX, Stuttgart

Study Site VIII, Tübingen